Market Place
Wouldnt it be wonderful if the products that are manufactured, have such great demand that, they fly off the shelves?
Our assessment of the drug shortage list in U.S. and Canada provides a list of opportunities, which are an outcome of shortage of the active pharmaceutical ingredient (API).
While
manufacturers struggle with ideas, we list opportunities that pharmaceutical
companies can capitalize upon.
Not all shortages are an outcome of manufacturing delays or quality problems; the growing demand for some products (especially injections) and lack of API supply of others is something that, if addressed, can become a potential windfall for companies (Read Forbes Millions to be made onGeneric Drugs?).
Old, established active ingredients, with limited supply options are usually the ones which have been driven to shortage. Utilizing the Pharma Compass database, a comprehensive list of existing and alternate supply options was prepared to assist the industry get started
| Product | Dosage Form | Active DMFs | Other potential suppliers |
|---|---|---|---|
| Trimipramine Maleate | Capsule | R. L. Fine Chem | |
| Tiopronin | Tablet | Okami Chemical Industry | |
| Methylphenidate HCl | Tablet, capsule | ||
|
Fluoxymesterone(Androxy) |
Tablet |
||
|
Tablet |
|||
|
Injectable |
|||
|
Injectable |
Boehringer Ingelheim facilities in St. Petersberg, Virginia, while listed have been excluded from the list on account of them shutting down the facility and subsequent plans of re-starting it not materializing.
Preventing drug shortages is a key focus area for the USFDA and Health Canada. For this reason, not only do the regulatory agencies have websites which lists all the shortages, but the USFDA has also developed their own mobile app to address concerns of all the stakeholders.
Addressing drug shortages is smart business since it ensures product availability, affordability and assurance along with profitability for the industry.
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : Russian Model by Din Muhammad Sumon // modification: added 'wanted' is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
